These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32928644)

  • 61. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
    Gomez A; Ferrer I
    Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Plasma Exosomes in Inherited Forms of Parkinson's Disease].
    Kulabukhova DG; Garaeva LA; Emelyanov AK; Senkevich KA; Gracheva EV; Miliukhina IV; Varfolomeeva EY; Timofeeva AA; Schwartsman AL; Shtam TA; Pchelina SN
    Mol Biol (Mosk); 2021; 55(2):338-345. PubMed ID: 33871446
    [TBL] [Abstract][Full Text] [Related]  

  • 63. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.
    Esteves AR; Swerdlow RH; Cardoso SM
    Exp Neurol; 2014 Nov; 261():206-16. PubMed ID: 24907399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. LRRK2 kinase in Parkinson's disease.
    Alessi DR; Sammler E
    Science; 2018 Apr; 360(6384):36-37. PubMed ID: 29622645
    [No Abstract]   [Full Text] [Related]  

  • 65. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
    Covy JP; Giasson BI
    Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Editorial: Proteomic alterations by mutations involved in Parkinson's disease and related disorders.
    Cardona F; Perez-Tur J
    Curr Protein Pept Sci; 2017; 18(7):654-655. PubMed ID: 28879817
    [No Abstract]   [Full Text] [Related]  

  • 67. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Trinh J; Zeldenrust FMJ; Huang J; Kasten M; Schaake S; Petkovic S; Madoev H; Grünewald A; Almuammar S; König IR; Lill CM; Lohmann K; Klein C; Marras C
    Mov Disord; 2018 Dec; 33(12):1857-1870. PubMed ID: 30357936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New Frontiers in Parkinson's Disease: From Genetics to the Clinic.
    Shihabuddin LS; Brundin P; Greenamyre JT; Stephenson D; Sardi SP
    J Neurosci; 2018 Oct; 38(44):9375-9382. PubMed ID: 30381429
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Leucine rich repeat kinase 2: a paradigm for pleiotropy.
    Lewis PA
    J Physiol; 2019 Jul; 597(14):3511-3521. PubMed ID: 31124140
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
    Yue Z; Lachenmayer ML
    Mov Disord; 2011 Jul; 26(8):1386-97. PubMed ID: 21538530
    [TBL] [Abstract][Full Text] [Related]  

  • 73. α-synuclein seed amplification in Parkinson's disease - Authors' reply.
    Siderowf A; Concha-Marambio L; Marek K; Soto C
    Lancet Neurol; 2023 Nov; 22(11):985-986. PubMed ID: 37863605
    [No Abstract]   [Full Text] [Related]  

  • 74. Parkinson disease genetics: too early to predict progression?
    Kuhlenbäumer G; Berg D
    Nat Rev Neurol; 2019 Nov; 15(11):625-626. PubMed ID: 31534210
    [No Abstract]   [Full Text] [Related]  

  • 75. Letter to the editor, "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Koga S; Dickson DW; Wszolek ZK
    Parkinsonism Relat Disord; 2020 Oct; 79():130. PubMed ID: 32921567
    [No Abstract]   [Full Text] [Related]  

  • 76. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease.
    Agin-Liebes J; Cortes E; Vonsattel JP; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 May; 74():76-77. PubMed ID: 31734038
    [No Abstract]   [Full Text] [Related]  

  • 77. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 78. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Hickman RA; Vonsattel JP; Agin-Liebes J; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 Oct; 79():131-132. PubMed ID: 32928644
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.